LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 58

Search options

  1. Article ; Online: CKD in Recipients of Nonkidney Solid Organ Transplants: A Review.

    Wiseman, Alexander C

    American journal of kidney diseases : the official journal of the National Kidney Foundation

    2021  Volume 80, Issue 1, Page(s) 108–118

    Abstract: Chronic kidney disease (CKD) after solid organ transplant is a common clinical presentation, affecting 10% to 20% of liver, heart, and lung transplant recipients and accounting for approximately 5% of the kidney transplant waiting list. The causes of CKD ...

    Abstract Chronic kidney disease (CKD) after solid organ transplant is a common clinical presentation, affecting 10% to 20% of liver, heart, and lung transplant recipients and accounting for approximately 5% of the kidney transplant waiting list. The causes of CKD are different for different types of transplants and are not all, or even predominantly, due to calcineurin inhibitor toxicity, with significant heterogeneity particularly in liver transplant recipients. Many solid organ transplant recipients with advanced CKD benefit from kidney transplantation but have a higher rate of death while waitlisted and higher mortality after transplant than the general kidney failure population. Recent organ allocation policies and proposals have attempted to address the appropriate identification and prioritization of candidates in need of a kidney transplant, either simultaneous with or after nonkidney transplant. Future research should focus on predictive factors for individuals identified as being at high risk for progression to kidney failure and death and on strategies to preserve kidney function and minimize the CKD burden in this unique patient population.
    MeSH term(s) Humans ; Kidney ; Kidney Transplantation/adverse effects ; Organ Transplantation ; Renal Insufficiency ; Renal Insufficiency, Chronic/epidemiology ; Renal Insufficiency, Chronic/surgery ; Risk Factors
    Language English
    Publishing date 2021-12-31
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 604539-x
    ISSN 1523-6838 ; 0272-6386
    ISSN (online) 1523-6838
    ISSN 0272-6386
    DOI 10.1053/j.ajkd.2021.10.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Simultaneous Liver-Kidney Transplant: Long-Term Management (Steroid Withdrawal and Safety Net Patients).

    Wiseman, Alexander C

    Clinical liver disease

    2019  Volume 13, Issue 6, Page(s) 176–179

    Language English
    Publishing date 2019-07-02
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2657644-2
    ISSN 2046-2484
    ISSN 2046-2484
    DOI 10.1002/cld.814
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Protecting Donors and Safeguarding Altruism in the United States: The Living Donor Protection Act.

    Wiseman, Alexander C

    Clinical journal of the American Society of Nephrology : CJASN

    2018  Volume 13, Issue 5, Page(s) 790–792

    MeSH term(s) Altruism ; Humans ; Kidney Transplantation ; Living Donors/ethics ; Living Donors/legislation & jurisprudence ; United States
    Language English
    Publishing date 2018-03-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2226665-3
    ISSN 1555-905X ; 1555-9041
    ISSN (online) 1555-905X
    ISSN 1555-9041
    DOI 10.2215/CJN.13681217
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Induction Therapy in Renal Transplantation: Why? What Agent? What Dose? We May Never Know.

    Wiseman, Alexander C

    Clinical journal of the American Society of Nephrology : CJASN

    2015  Volume 10, Issue 6, Page(s) 923–925

    MeSH term(s) Antibodies, Monoclonal, Humanized/therapeutic use ; Antilymphocyte Serum/therapeutic use ; Calcineurin Inhibitors/therapeutic use ; Female ; Humans ; Immunosuppressive Agents/therapeutic use ; Kidney Transplantation/methods ; Living Donors ; Male ; Mycophenolic Acid/therapeutic use ; Steroids/therapeutic use ; Tacrolimus/therapeutic use
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antilymphocyte Serum ; Calcineurin Inhibitors ; Immunosuppressive Agents ; Steroids ; Mycophenolic Acid (HU9DX48N0T) ; Tacrolimus (WM0HAQ4WNM)
    Language English
    Publishing date 2015-05-15
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2226665-3
    ISSN 1555-905X ; 1555-9041
    ISSN (online) 1555-905X
    ISSN 1555-9041
    DOI 10.2215/CJN.03800415
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Immunosuppressive Medications.

    Wiseman, Alexander C

    Clinical journal of the American Society of Nephrology : CJASN

    2015  Volume 11, Issue 2, Page(s) 332–343

    Abstract: Immunosuppressive agents are commonly used in the nephrologist's practice in the treatment of autoimmune and immune-mediated diseases and transplantation, and they are investigational in the treatment of AKI and ESRD. Drug development has been rapid over ...

    Abstract Immunosuppressive agents are commonly used in the nephrologist's practice in the treatment of autoimmune and immune-mediated diseases and transplantation, and they are investigational in the treatment of AKI and ESRD. Drug development has been rapid over the past decades as mechanisms of the immune response have been better defined both by serendipity (the discovery of agents with immunosuppressive activity that led to greater understanding of the immune response) and through mechanistic study (the study of immune deficiencies and autoimmune diseases and the critical pathways or mutations that contribute to disease). Toxicities of early immunosuppressive agents, such as corticosteroids, azathioprine, and cyclophosphamide, stimulated intense investigation for agents with more specificity and less harmful effects. Because the mechanisms of the immune response were better delineated over the past 30 years, this specialty is now bestowed with a multitude of therapeutic options that have reduced rejection rates and improved graft survival in kidney transplantation, provided alternatives to cytotoxic therapy in immune-mediated diseases, and opened new opportunities for intervention in diseases both common (AKI) and rare (atypical hemolytic syndrome). Rather than summarizing clinical indications and clinical trials for all currently available immunosuppressive medications, the purpose of this review is to place these agents into mechanistic context together with a brief discussion of unique features of development and use that are of interest to the nephrologist.
    MeSH term(s) Animals ; Antibodies, Monoclonal/therapeutic use ; Autoimmune Diseases/diagnosis ; Autoimmune Diseases/drug therapy ; Autoimmune Diseases/immunology ; B-Lymphocytes/drug effects ; B-Lymphocytes/immunology ; Graft Rejection/diagnosis ; Graft Rejection/immunology ; Graft Rejection/prevention & control ; Graft Survival/drug effects ; Humans ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Kidney Diseases/diagnosis ; Kidney Diseases/drug therapy ; Kidney Diseases/immunology ; Kidney Transplantation/adverse effects ; Molecular Targeted Therapy ; Signal Transduction/drug effects ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; Immunosuppressive Agents
    Language English
    Publishing date 2015-07-13
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2226665-3
    ISSN 1555-905X ; 1555-9041
    ISSN (online) 1555-905X
    ISSN 1555-9041
    DOI 10.2215/CJN.08570814
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Novel indications for referral and care for simultaneous liver kidney transplant recipients.

    Lum, Erik L / Bunnapradist, Suphamai / Wiseman, Alexander C / Gurakar, Ahmet / Ferrey, Antoney / Reddy, Uttam / Al Ammary, Fawaz

    Current opinion in nephrology and hypertension

    2024  Volume 33, Issue 3, Page(s) 354–360

    Abstract: Purpose of review: Kidney dysfunction is challenging in liver transplant candidates to determine whether it is reversible or not. This review focuses on the pertinent data on how to best approach liver transplant candidates with kidney dysfunction in ... ...

    Abstract Purpose of review: Kidney dysfunction is challenging in liver transplant candidates to determine whether it is reversible or not. This review focuses on the pertinent data on how to best approach liver transplant candidates with kidney dysfunction in the current era after implementing the simultaneous liver kidney (SLK) allocation policy and safety net.
    Recent findings: The implementation of the SLK policy inverted the steady rise in SLK transplants and improved the utilization of high-quality kidneys. Access to kidney transplantation following liver transplant alone (LTA) increased with favorable outcomes. Estimating GFR in liver transplant candidates remains challenging, and innovative methods are needed. SLK provided superior patient and graft survival compared to LTA only for patients with advanced CKD and dialysis at least 3 months. SLK can provide immunological protection against kidney rejection in highly sensitized candidates. Post-SLK transplant care is complex, with an increased risk of complications and hospitalization.
    Summary: The SLK policy improved kidney access and utilization. Transplant centers are encouraged, under the safety net, to reserve SLK for liver transplant candidates with advanced CKD or dialysis at least 3 months while allowing lower thresholds for highly sensitized patients. Herein, we propose a practical approach to liver transplant candidates with kidney dysfunction.
    MeSH term(s) Humans ; Kidney Transplantation/methods ; Renal Dialysis/adverse effects ; Risk Factors ; Kidney ; Renal Insufficiency ; Graft Survival ; Liver ; Referral and Consultation ; Renal Insufficiency, Chronic/diagnosis ; Renal Insufficiency, Chronic/surgery
    Language English
    Publishing date 2024-02-12
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 1151092-4
    ISSN 1473-6543 ; 1535-3842 ; 1062-4813 ; 1062-4821
    ISSN (online) 1473-6543 ; 1535-3842
    ISSN 1062-4813 ; 1062-4821
    DOI 10.1097/MNH.0000000000000970
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Kidney transplant options for the diabetic patient.

    Wiseman, Alexander C

    Transplantation reviews (Orlando, Fla.)

    2013  Volume 27, Issue 4, Page(s) 112–116

    Abstract: For patients with diabetes and progressive chronic kidney disease, kidney transplantation is the optimal mode of renal replacement therapy, with or without a pancreas transplant. Additional benefits of pancreas transplant have become increasingly ... ...

    Abstract For patients with diabetes and progressive chronic kidney disease, kidney transplantation is the optimal mode of renal replacement therapy, with or without a pancreas transplant. Additional benefits of pancreas transplant have become increasingly apparent due to advances in surgical outcomes and immunosuppression, and may be reasonably considered even in selected patients with type 2 diabetes. In general, pancreas transplantation is associated with long-term survival advantages despite an increased short-term morbidity and mortality risk. This is true with simultaneous pancreas kidney transplantation or pancreas after kidney transplantation compared to kidney transplantation alone, regardless of kidney donor status (living or deceased). Individual patient preferences, comorbidities, and expected waiting time influence selection of transplant modality, rather than a clear survival benefit of one strategy versus the other. In selected patients with type 2 diabetes, recent outcomes data support cautious utilization of simultaneous pancreas kidney transplantation when a living kidney donor transplant is not an option. The purpose of this review is to summarize current data regarding kidney and pancreas transplant treatment options in patients with both type 1 and 2 diabetes and the influence of current organ allocation policies to better understand the advantages and disadvantages of each of these strategies.
    MeSH term(s) Diabetes Complications/complications ; Diabetes Complications/mortality ; Diabetes Complications/surgery ; Global Health ; Graft Survival ; Humans ; Kidney Transplantation/methods ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/mortality ; Renal Insufficiency, Chronic/surgery ; Survival Rate/trends
    Language English
    Publishing date 2013-10
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 639400-0
    ISSN 1557-9816 ; 0955-470X
    ISSN (online) 1557-9816
    ISSN 0955-470X
    DOI 10.1016/j.trre.2013.07.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Live donor kidney - PAK versus SPK: how to decide?

    Stites, Erik / Wiseman, Alexander C

    Current opinion in organ transplantation

    2017  Volume 22, Issue 4, Page(s) 377–381

    Abstract: Purpose of review: Patients with type 1 diabetes and end stage renal disease face a complex choice when considering the relative risks and benefits of kidney transplant alone with or without subsequent pancreas after kidney transplant (PAK) or ... ...

    Abstract Purpose of review: Patients with type 1 diabetes and end stage renal disease face a complex choice when considering the relative risks and benefits of kidney transplant alone with or without subsequent pancreas after kidney transplant (PAK) or simultaneous kidney pancreas transplant (SPK).
    Recent findings: SPK is considered the optimal treatment regarding long-term patient survival, but when also faced with the option of living donor kidney transplant with the potential for PAK later, the ideal option is less clear.
    Summary: This review summarizes the current literature regarding SPK, living donor kidney transplant alone, and PAK transplant outcomes and examines the relative risks of pre- and posttransplant variables that impact patient and graft survival to help inform this complex treatment decision.
    Language English
    Publishing date 2017-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1390429-2
    ISSN 1531-7013 ; 1087-2418
    ISSN (online) 1531-7013
    ISSN 1087-2418
    DOI 10.1097/MOT.0000000000000435
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Removing financial disincentives to organ donation: an acceptable next step?

    Wiseman, Alexander C

    Clinical journal of the American Society of Nephrology : CJASN

    2012  Volume 7, Issue 12, Page(s) 1917–1919

    MeSH term(s) Attitude of Health Personnel ; Female ; Humans ; Kidney Diseases/psychology ; Male ; Motivation ; Public Opinion ; Tissue Donors/supply & distribution ; Tissue and Organ Procurement/economics
    Language English
    Publishing date 2012-12
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 2226665-3
    ISSN 1555-905X ; 1555-9041
    ISSN (online) 1555-905X
    ISSN 1555-9041
    DOI 10.2215/CJN.11021012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Pancreas transplant options for patients with type 1 diabetes mellitus and chronic kidney disease: simultaneous pancreas kidney or pancreas after kidney?

    Wiseman, Alexander C

    Current opinion in organ transplantation

    2012  Volume 17, Issue 1, Page(s) 80–86

    Abstract: Purpose of review: For patients with type 1 diabetes and chronic kidney disease, the benefits of kidney transplantation vs. dialysis have long been appreciated. However, until recently, the added benefit of pancreas transplantation has been less well ... ...

    Abstract Purpose of review: For patients with type 1 diabetes and chronic kidney disease, the benefits of kidney transplantation vs. dialysis have long been appreciated. However, until recently, the added benefit of pancreas transplantation has been less well defined.
    Recent findings: A number of articles now suggest a long-term survival advantage with simultaneous pancreas kidney (SPK) transplantation, with concurrent improvements in pancreas after kidney transplantation. Although supportive of pancreas transplantation as the preferred therapy for this population, this creates a difficult decision-making process for the patient with type 1 diabetes mellitus and a living donor: should one proceed with living donor transplant and consider pancreas transplantation subsequently, or should one wait for an SPK transplant?
    Summary: The purpose of this review is to synthesize current data regarding pancreas treatment options and couple this with a discussion of current organ utilization to better understand the advantages and disadvantages of each of these strategies. This in turn may inform clinicians and aid in counseling for the individual patient.
    MeSH term(s) Decision Making ; Diabetes Mellitus, Type 1/mortality ; Diabetes Mellitus, Type 1/surgery ; Diabetic Nephropathies/etiology ; Diabetic Nephropathies/mortality ; Diabetic Nephropathies/surgery ; Graft Survival ; Humans ; Kidney Transplantation/methods ; Kidney Transplantation/mortality ; Living Donors ; Pancreas Transplantation/methods ; Pancreas Transplantation/mortality ; Quality of Life ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/mortality ; Renal Insufficiency, Chronic/surgery ; Risk Factors ; Time Factors ; Waiting Lists
    Language English
    Publishing date 2012-02
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1390429-2
    ISSN 1531-7013 ; 1087-2418
    ISSN (online) 1531-7013
    ISSN 1087-2418
    DOI 10.1097/MOT.0b013e32834ee73a
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top